Breaking News, Financial News

Financial Report: Dendreon

Adds 42 new Provenge accounts

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dendreon 2Q Revenues: $73.3 million (-8%) 2Q Loss: $68.8 million (-28%) YTD Revenues: $140.9 million (-13%) YTD Loss: $140.8 million (-30%) Comments: The company added 42 new accounts in the quarter for Provenge. Urology sales were up 37% in the quarter. Total operating expenses were $128.5 million in the quarter, down 21%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters